(-)-CGP 12177 causes cardiostimulation and binds to cardiac putative β4-adrenoceptors in both wild-type and β3-adrenoceptor knockout mice

被引:77
作者
Kaumann, AJ [1 ]
Preitner, F
Sarsero, D
Molenaar, P
Revelli, JP
Giacobino, JP
机构
[1] Babraham Inst, Cambridge CB2 4AT, England
[2] Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva 4, Switzerland
[3] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3052, Australia
关键词
D O I
10.1124/mol.53.4.670
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Some blockers of beta(1)- and beta(2)-adrenoceptors cause cardiostimulant effects through an atypical beta-adrenoceptor (putative beta(4)-adrenoceptor) that resembles the beta(3)-adrenoceptor. It is likely but not proven that the putative beta(4)-adrenoceptor is genetically distinct from the beta(3)-adrenoceptor. We therefore investigated whether or not the cardiac atypical beta-adrenoceptor could mediate agonist effects in mice lacking a functional beta(3)-adrenoceptor gene (beta(3)KO). (-)-CGP 12177, a beta(1)- and beta(2)-adrenoceptor blocker that causes agonist effects through both beta(3)-adrenoceptors and cardiac putative beta(4)-adrenoceptors, caused cardiostimulant effects that were not different in atria from wild-type (WT) mice and beta(3)KO mice. The effects of (-)-CGP 12177 were resistant to blockade by (-)-propranolol (200 nM) but were blocked by (-)-bupranolol (1 mu M) with an equilibrium dissociation constant of 15 nM in WT and 17 nM in beta(3)KO. (-)-[H-3]CGP 12177 labeled a similar density of the putative beta(4)-adrenoceptor in ventricular membranes from the hearts of both WT (B-max = 52 fmol/mg protein) and beta(3)KO (B-max = 53 fmol/mg protein) mice. The affinity of (-)-[H-3]CGP 12177 for the cardiac putative beta(4)-adrenoceptor was not different between WT (K-d = 46 nM) and beta(3)KO (K-d = 40 nM). These results provide definitive evidence that the cardiac putative beta(4)-adrenoceptor is distinct from the beta(3)-adrenoceptor.
引用
收藏
页码:670 / 675
页数:6
相关论文
共 39 条
[1]   BETA(3)-ADRENOCEPTOR AND ATYPICAL BETA-ADRENOCEPTOR [J].
ARCH, JRS ;
KAUMANN, AJ .
MEDICINAL RESEARCH REVIEWS, 1993, 13 (06) :663-729
[2]  
ARCH JRS, 1997, PHARM REV COMMUN, V9, P141
[3]   DISTRIBUTION OF BETA(3)-ADRENOCEPTOR MESSENGER-RNA IN HUMAN TISSUES [J].
BERKOWITZ, DE ;
NARDONE, NA ;
SMILEY, RM ;
PRICE, DT ;
KREUTTER, DK ;
FREMEAU, RT ;
SCHWINN, DA .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 289 (02) :223-228
[4]   MEDIATION OF MOST ATYPICAL EFFECTS BY SPECIES HOMOLOGS OF THE BETA(3)-ADRENOCEPTOR [J].
BLIN, N ;
NAHMIAS, C ;
DRUMARE, MF ;
STROSBERG, AD .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 112 (03) :911-919
[6]   Lipolytic effects of conventional beta 3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative beta 4-adrenoceptor [J].
Galitzky, J ;
Langin, D ;
Verwaerde, P ;
Montastruc, JL ;
Lafontan, M ;
Berlan, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (06) :1244-1250
[7]   Functional beta(3)-adrenoceptor in the human heart [J].
Gauthier, C ;
Tavernier, G ;
Charpentier, F ;
Langin, D ;
LeMarec, H .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02) :556-562
[8]   BETA(3)-ADRENOCEPTOR - AN UPDATE [J].
GIACOBINO, JP .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 132 (04) :377-385
[9]  
GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895
[10]  
GRANNEMAN JG, 1993, MOL PHARMACOL, V44, P264